Table 1 Population description.
Total (n = 51) | |
|---|---|
Age (years) – median (IQR) | 61 (58–66) |
≥ 60 years – n(%) | 35 (68.6) |
≥ 65 years – n(%) | 19 (37.3) |
Sex (male) – n(%) | 35 (68.6) |
Monoclonal component – n(%) | |
IgG | 29 (56.9) |
IgA | 12 (23.5) |
Free light chain only | 10 (19.6) |
ISS disease stage – n(%) | |
I | 18 (42) |
II | 11 (26) |
III | 14 (32) |
Missing | 8 |
Cytogenetic profile risk – n(%) | |
Standard risk | 27 (71) |
High risk | 11 (29) |
del(17p) | 6 (16) |
t(4;14) | 5 (13) |
Missing | 13 |
Patients exposed to lenalidomide in 1st line of therapy – n(%) | 7 (13.7) |
Time between start of 1st and 2nd line of therapy (month) – median (IQR) | 40.2 (30.9–53.4) |
Time between 1st and 2nd ASCT (month) – median (IQR) | 40.4 (31.7–55.1) |
Time between start of 2nd line of therapy and 2nd ASCT (months) – median (IQR) | 5.9 (4.8–8.1) |
Number of cycles of KRd in induction – n (%) | |
3 or 4 | 24 (50.0) |
5 or 6 | 16 (33.3) |
7 to 12 | 8 (16.7) |
Missing | 3 |
